For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 17,500 | |||
| Acquired in-process research and development | 68,088 | |||
| General and administrative | 16,678 | |||
| Total operating expenses | 102,266 | |||
| Loss from operations | -102,266 | |||
| Other income, net | 1,236 | |||
| Sermonix pre-funded warrant change in fair value | 4,579 | |||
| Net loss | -105,609 | |||
| Unrealized (loss) gain on available-for-sale securities | -5 | |||
| Comprehensive loss attributable to common stockholders | -105,614 | |||
| Basic EPS | -24.7 | |||
| Diluted EPS | -24.7 | |||
| Basic Average Shares | 4,275,762 | |||
| Diluted Average Shares | 4,275,762 | |||
LeonaBio, Inc. (LONA)
LeonaBio, Inc. (LONA)